{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:25:29Z","timestamp":1752229529675,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["No.2020YFSY0030","No.2020YFSY0030"],"award-info":[{"award-number":["No.2020YFSY0030","No.2020YFSY0030"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant No.81871578"],"award-info":[{"award-number":["Grant No.81871578"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>One popular and well-established marker for the immune checkpoint blockade (ICB) response is tumor mutation burden (TMB). Persistent TMB (pTMB), a subset of TMB, provides a better indicator to predict patient ICB therapy outcomes, as shown by some studies. Immune checkpoint drugs have significantly changed how melanoma is treated in recent years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, we integrated the TCGA-SKCM database and data of pTMB of TCGA from the paper that first mentioned pTMB and analyzed mutational and Immune characteristics associated with pTMB level in SKCM. Next, the predictive DEGs were identified the subgroups of pTMB by Cox regression and LASSO analyses to construct a pTMB-related signature. Finally, the expression and Biological functions of signature genes was detected, and further validated in vitro assay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the current research, we explored the mutational and immunological features related to the level of TMB in cutaneous melanoma (CM). The high-pTMB subgroup exhibited an increasing incidence of gene changes and higher levels of immune cell infiltration. Subsequently, we established a pTMB-related signature based on the predictive DEGs and found the biological features and immune-associated variables between two distinct risk groups. Lastly, the results of the clinical sample validation demonstrated that the expression of IL17REL was down-regulated in the collected samples of individuals with CM. The in vitro assay results indicated that IL17REL effectively suppressed the proliferation, clonality, and migration of CM cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, we have developed a prediction model associated with TMB and subsequently validated the potential influence of IL17REL on Overall Survival (OS) in patients diagnosed with melanoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05843-x","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T05:02:06Z","timestamp":1718859726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Developing a prognostic model for skin melanoma based on the persistent tumor mutation burden and determining IL17REL as a therapeutic target"],"prefix":"10.1007","volume":"150","author":[{"given":"Mingze","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"3","key":"5843_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM et al (2017) Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 7(3):264\u2013276","journal-title":"Cancer Discov"},{"issue":"5","key":"5843_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M et al (2022) Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 158(5):495\u2013503","journal-title":"JAMA Dermatol"},{"issue":"7791","key":"5843_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A et al (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791):561\u2013565","journal-title":"Nature"},{"issue":"10304","key":"5843_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002\u20131014","journal-title":"Lancet"},{"issue":"6","key":"5843_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41568-023-00565-7","volume":"23","author":"PP Centeno","year":"2023","unstructured":"Centeno PP, Pavet V, Marais R (2023) The journey from melanocytes to melanoma. Nat Rev Cancer 23(6):372\u2013390","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5843_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9(1):34","journal-title":"Genome Med"},{"issue":"1","key":"5843_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M et al (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248\u2013262","journal-title":"Cell Rep"},{"issue":"6322","key":"5843_CR8","doi-asserted-by":"publisher","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli T, Uno H, Wooten EC et al (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355(6322):eaaf8399","journal-title":"Science"},{"issue":"8","key":"5843_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","volume":"24","author":"J Debnath","year":"2023","unstructured":"Debnath J, Gammoh N, Ryan KM (2023) Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol 24(8):560\u2013575","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7916","key":"5843_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41586-022-04789-9","volume":"606","author":"RM Drews","year":"2022","unstructured":"Drews RM, Hernando B, Tarabichi M et al (2022) A pan-cancer compendium of chromosomal instability. Nature 606(7916):976\u2013983","journal-title":"Nature"},{"issue":"4","key":"5843_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ng.553","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke A, Balschun T, Sina C et al (2010) Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet 42(4):292\u2013294","journal-title":"Nat Genet"},{"issue":"2","key":"5843_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM et al (2019) Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell 35(2):238","journal-title":"Cancer Cell"},{"issue":"1","key":"5843_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C et al (2018) Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res 37(1):327","journal-title":"J Exp Clin Cancer Res"},{"issue":"7791","key":"5843_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J et al (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549\u2013555","journal-title":"Nature"},{"issue":"7","key":"5843_CR15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn D, Budhu S, Kraehenbuehl L et al (2023) T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186(7):1432","journal-title":"Cell"},{"key":"5843_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.addr.2015.10.007","volume":"97","author":"AW Holle","year":"2016","unstructured":"Holle AW, Young JL, Spatz JP (2016) In vitro cancer cell-ECM interactions inform in vivo cancer treatment. Adv Drug Deliv Rev 97:270\u2013279","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"5843_CR17","first-page":"285","volume":"70","author":"S Hu","year":"2021","unstructured":"Hu S, Vich Vila A, Gacesa R et al (2021) Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD. Gut 70(2):285\u2013296","journal-title":"Gut"},{"issue":"2","key":"5843_CR18","doi-asserted-by":"publisher","first-page":"e003716","DOI":"10.1136\/jitc-2021-003716","volume":"10","author":"X Jie","year":"2022","unstructured":"Jie X, Chen Y, Zhao Y et al (2022) Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer. J Immunother Cancer 10(2):e003716","journal-title":"J Immunother Cancer"},{"issue":"4","key":"5843_CR19","doi-asserted-by":"publisher","first-page":"e006454","DOI":"10.1136\/jitc-2022-006454","volume":"11","author":"J Jung","year":"2023","unstructured":"Jung J, Heo YJ, Park S (2023) High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer 11(4):e006454","journal-title":"J Immunother Cancer"},{"issue":"4","key":"5843_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora S, Nagler A, Wargo JA et al (2022) Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer 22(4):195\u2013207","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5843_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.immuni.2023.02.011","volume":"56","author":"M Leung","year":"2023","unstructured":"Leung M, Mcgranahan N (2023) Persistence is key: refining immunotherapy response prediction. Immunity 56(3):472\u2013474","journal-title":"Immunity"},{"issue":"1","key":"5843_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41467-021-27889-y","volume":"13","author":"CH Li","year":"2022","unstructured":"Li CH, Haider S, Boutros PC (2022) Age influences on the molecular presentation of tumours. Nat Commun 13(1):208","journal-title":"Nat Commun"},{"issue":"2","key":"5843_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA et al (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2):400\u2013416","journal-title":"Cell"},{"issue":"12","key":"5843_CR24","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D et al (2019) Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med 25(12):1916\u20131927","journal-title":"Nat Med"},{"issue":"7913","key":"5843_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M \u0141uksza","year":"2022","unstructured":"\u0141uksza M, Sethna ZM, Rojas LA et al (2022) Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606(7913):389\u2013395","journal-title":"Nature"},{"key":"5843_CR26","doi-asserted-by":"publisher","first-page":"1003656","DOI":"10.3389\/fcell.2022.1003656","volume":"10","author":"K Luo","year":"2022","unstructured":"Luo K, Liu S, Shen X et al (2022) Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1\/PDL1 therapy [J]. Front Cell Dev Biol 10:1003656","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"5843_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pili\u00e9 PG, Rashid NU, Voorwerk L et al (2021) High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661\u2013672","journal-title":"Ann Oncol"},{"issue":"2","key":"5843_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","volume":"29","author":"N Niknafs","year":"2023","unstructured":"Niknafs N, Balan A, Cherry C et al (2023) Persistent mutation burden drives sustained anti-tumor immune responses. Nat Med 29(2):440\u2013449","journal-title":"Nat Med"},{"issue":"5","key":"5843_CR29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","volume":"7","author":"JR Patrinely","year":"2021","unstructured":"Patrinely JR, Johnson R, Lawless AR et al (2021) Chronic immune-related adverse events following adjuvant Anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol 7(5):744\u2013748","journal-title":"JAMA Oncol"},{"issue":"7953","key":"5843_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","volume":"615","author":"C Puig-Saus","year":"2023","unstructured":"Puig-Saus C, Sennino B, Peng S et al (2023) Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature 615(7953):697\u2013704","journal-title":"Nature"},{"key":"5843_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3560","author":"W Roh","year":"2017","unstructured":"Roh W, Chen P-L, Reuben A et al (2017) Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aah3560","journal-title":"Sci Transl Med"},{"issue":"1","key":"5843_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-021-01490-9","volume":"21","author":"S Serrat\u00ec","year":"2022","unstructured":"Serrat\u00ec S, Guida M, Di Fonte R et al (2022) Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer 21(1):20","journal-title":"Mol Cancer"},{"issue":"4","key":"5843_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48(4):812\u2013830","journal-title":"Immunity"},{"issue":"3","key":"5843_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","volume":"41","author":"B Virassamy","year":"2023","unstructured":"Virassamy B, Caramia F, Savas P et al (2023) Intratumoral CD8+ T\u00a0cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell 41(3):585","journal-title":"Cancer Cell"},{"issue":"5","key":"5843_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41568-021-00344-2","volume":"21","author":"H Xia","year":"2021","unstructured":"Xia H, Green DR, Zou W (2021) Autophagy in tumour immunity and therapy. Nat Rev Cancer 21(5):281\u2013297","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5843_CR36","doi-asserted-by":"publisher","first-page":"7480","DOI":"10.1038\/s41598-023-34698-4","volume":"13","author":"L Yanan","year":"2023","unstructured":"Yanan L, Hui L, Zhuo C et al (2023) Comprehensive analysis of mitophagy in HPV-related head and neck squamous cell carcinoma. Sci Rep 13(1):7480","journal-title":"Sci Rep"},{"issue":"4","key":"5843_CR37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/pathogens12040572","volume":"12","author":"M Yuhan Sun","year":"2023","unstructured":"Yuhan Sun M, Khan AAK, Mangiola S et al (2023) IL17RB and IL17REL expression are associated with improved prognosis in HPV-infected head and neck squamous cell carcinomas. Pathogens 12(4):572","journal-title":"Pathogens"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05843-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:54:52Z","timestamp":1720522492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05843-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["5843"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05843-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has a financial interest in any of the products or devices mentioned in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Changhai Hospital and was carried out according to the procedure of Changhai Hospital clinical research center biobank experiment.All patients who provided clinical specimens signed the written informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"313"}}